uniQure Announces Data from Phase I/II AMT-060 Clinical Trial

Note: The below is an edited version of a press release by UniQure. The original release can be read in it’s entirety here.

On June 11, 2016, uniQure N.V. announced that additional data from its Phase I/II clinical trial of AMT-060 in hemophilia B patients were presented at the 21^st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. Study investigator Dr. Frank Leebeek, Professor of Hematology at Erasmus University Medical Center in Rotterdam, gave an oral presentation of a comprehensive overview of results from five patients that received a single administration of uniQure’s novel gene therapy, AMT-060. Data from low-dose cohort showed durable and therapeutically relevant factor IX (FIX) expression, with a median FIX activity for the five patients in the trial at 5.4.
Read the press release from uniQure in it’s entirety here.